ThromboGenics Ocriplasmin’s Advisory Panel Likely To Focus On Safety
This article was originally published in The Pink Sheet Daily
Executive Summary
ThromboGenics will seek to convince the Dermatologic and Ophthalmic Drugs Advisory Committee that further safety studies should not be made a condition of approval of its ocriplasmin for symptomatic vitreomacular adhesion, including macular hole.